Algeria vs Viet Nam: Average cost of multi drug-resistant tuberculosis treatment
Algeria
440 constant 2022 US$
in 2022
Viet Nam
458 constant 2022 US$
in 2024
Algeria rank
85th
Viet Nam rank
83rd
Average cost of multi drug-resistant tuberculosis treatment over time
- Algeria
- Viet Nam
How they compare
Viet Nam currently reports 458 constant 2022 US$ against 440 constant 2022 US$ in Algeria, a difference of 18 constant 2022 US$.
The two have swapped places 4 times across 5 shared years of data; in 2017 it was Viet Nam ahead.
Algeria ranks 85th and Viet Nam ranks 83rd of 92 countries.
Algeria has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Algeria | Viet Nam | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 862.5 constant 2022 US$ | 713 constant 2022 US$ | 149.5 constant 2022 US$ | Algeria |
| 2020s | 680 constant 2022 US$ | 611 constant 2022 US$ | 69 constant 2022 US$ | Algeria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Algeria or Viet Nam?
- Viet Nam, at 458 constant 2022 US$ against 440 constant 2022 US$ in Algeria as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Algeria and Viet Nam?
- 18 constant 2022 US$, with Viet Nam ahead.
- How many years of comparable data are there for Algeria and Viet Nam?
- 5 years are reported by both, from 2017 to 2022.
- How do Algeria and Viet Nam rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Algeria ranks 85th and Viet Nam ranks 83rd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.